An automated insulin delivery system from pregestational care to postpartum in women with type 1 diabetes. Preliminary experience with telemedicine in 6 patients
Acta Diabetologica · 2024
DOI: 10.1007/s00592-024-02315-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, 2024. Verfasst von Raffaella Fresa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Diabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Telemedicine, Insulin Infusion Systems, Insulin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
INTRODUCTION: The use of most commercially available automated insulin delivery (AID) systems is off-label in pregnancy. However, an increasing number of women with type 1 diabetes (T1D) use such devices throughout pregnancy and delivery. We analysed the data of six women with T1D from a single centre (Diabetology Outpatient Clinic of District-63/Asl Salerno, Italy) who were able to start and maintain AID therapy with the MiniMed™ 780G (Medtronic, Minneapolis, MN, USA) throughout the pregestational care period, pregnancy, delivery, and postpartum. METHODS: We retrospectively collected data from six patients with T1D who received training and initiation on use of the MiniMed™ 780G and attended follow-up visits throughout pregnancy (these visits were virtual because of the COVID-19 pandemic). All patients maintained their devices in the closed-loop setting throughout pregnancy and during labour and delivery. We analysed data from the pregestational phase to the first 30 days postpartum. RESULTS: All patients achieved the recommended metabolic goals before conception [median time in range (TIR) of 88% for 70-180 mg/dL; median pregnancy-specific TIR 63-140 mg/dL (ps-TIR) of 66% and maintained the ps-TIR until delivery (median ps-TIR 83%). All patients had slightly better metrics during the night than during the day, with a very low time below range of < 63 mg/dL. Optimal glycaemic values were also maintained on the day of labour and delivery (median ps-TIR 92.5%) and in the first 30 days postpartum, with no severe hypoglycaemia. The only neonatal complications were jaundice in one child and an interatrial defect in another child. CONCLUSION: In our well-selected and trained patients, use of the MiniMed™ 780G helped to achieve and maintain ps-metrics from the pregestational period to delivery despite the fact that the algorithm is not set to achieve the ambitious glycaemic values recommended for pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetology Outpatient Clinic , Asl Salerno, District 63, Salerno, Italy.
- Diabetology Unit, San Paolo Hospital, ASL Roma 4, Civitavecchia, Rome, Italy. olimpia.bitterman@gmail.com.
- Israelitico Hospital, Rome, Italy.
- International Medical University Unicamillus, Rome, Italy.
- Cdc Santa Famiglia, Rome, Italy.
Zitieren
APA
Fresa, R., Bitterman, O., Cavallaro, V., Di Filippi, M., Dimarzo, D., Mosca, C., Nappi, F., Rispoli, M., & Napoli, A. (2024). An automated insulin delivery system from pregestational care to postpartum in women with type 1 diabetes. Preliminary experience with telemedicine in 6 patients. Acta Diabetologica. https://doi.org/10.1007/s00592-024-02315-z
Vancouver
Fresa R, Bitterman O, Cavallaro V, Di Filippi M, Dimarzo D, Mosca C, et al. An automated insulin delivery system from pregestational care to postpartum in women with type 1 diabetes. Preliminary experience with telemedicine in 6 patients. Acta Diabetologica. 2024. doi:10.1007/s00592-024-02315-z
BibTeX
@article{Fresa2024,
author = {Fresa, Raffaella and Bitterman, Olimpia and Cavallaro, Vincenzo and Di Filippi, Marianna and Dimarzo, Daniela and Mosca, Carmela and Nappi, Francesca and Rispoli, Marilena and Napoli, Angela},
title = {An automated insulin delivery system from pregestational care to postpartum in women with type 1 diabetes. Preliminary experience with telemedicine in 6 patients},
journal = {Acta Diabetologica},
year = {2024},
doi = {10.1007/s00592-024-02315-z}
}
EUVIMED